ABSTRACT
BACKGROUND: Novel direct-acting antiviral agents have shown great efficacy and tolerability in HCV-monoinfected patients. However, data are lacking regarding their efficacy and safety in HIV/HCV-genotype (GT) 4-coinfected patients. METHODS: A single-centre, prospective study including HIV/HCV-GT 4-coinfected patients who were treated with sofosbuvir and daclatasvir (SOF/DCV) was conducted for 12 wk. Sustained virological response (SVR) at week 12 post-treatment (SVR12), adverse events (AEs) and changes in liver stiffness measurement (LSM) at SVR12 in comparison with baseline were evaluated. RESULTS: SVR12 was achieved in 46 of 50 patients (92%). No significant difference in SVR12 was noticed among patients who received antiretroviral therapy (ART) regimens compared with those who did not receive ART regimens or between those with insignificant fibrosis (Subject(s)
Coinfection
, HIV Infections
, Hepatitis C, Chronic
, Antiviral Agents/therapeutic use
, Carbamates
, Coinfection/drug therapy
, Drug Therapy, Combination
, Genotype
, HIV Infections/complications
, HIV Infections/drug therapy
, Hepacivirus/genetics
, Hepatitis C, Chronic/complications
, Hepatitis C, Chronic/drug therapy
, Humans
, Imidazoles
, Liver Cirrhosis/complications
, Liver Cirrhosis/drug therapy
, Prospective Studies
, Pyrrolidines
, Ribavirin/therapeutic use
, Sofosbuvir/therapeutic use
, Sustained Virologic Response
, Treatment Outcome
, Valine/analogs & derivatives
